Article Details

Sotagliflozin significantly reduces MACE in high-risk type 2 diabetes | springermedicine.com

Retrieved on: 2025-03-03 18:09:56

Tags for this article:

Click the tags to see associated articles and topics

Sotagliflozin significantly reduces MACE in high-risk type 2 diabetes | springermedicine.com. View article details on hiswai:

Excerpt

Dual SGLT1/2 inhibitor sotagliflozin significantly reduces major adverse cardiac events in people with type 2 diabetes, CKD, and high CV risk.

Article found on: www.springermedicine.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up